ANAB — Stock Film
STOCK FILMSCENE 1/11ANAB · $64.81
Stock Expert AI presents
ANAB
AnaptysBio, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
AnaptysBio, Inc. A quick introduction.

On the stock market since 2017, it operates in the world of health and science. It has 136 employees. Now — the numbers.

on the stock market since 2017
136 employees
$1.9B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.1.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 39% a year over the last 4 years. Red columns mark years that ended in a loss.

$63.2M
2021
$10.3M
2022
$17.2M
2023
$91.3M
2024
$234.6M
2025
In the vault right now:
$0
DEBT: $14.1M
At this pace, that money lasts about 23.6 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
93
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
58
average

The cash pile is strong; debt and other items pull the grade toward the middle.

VALUATION
55
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
88
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
93
very strong

The stock has been running stronger than the market lately.

No real weak spot in any of the five subjects — a balanced report card.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Sales are growing fast10/10
Fat profit per sale, but shrinking10/10
A strong cash pile8/10
WEAK SPOTS
Executives aren’t buying3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
Bumpy, but the direction is up.

The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 184% a year on average.

2
THE BRIGHT SIDE · 2/3
The product is selling

Sales run at $234.6M a year. A small number, but proof the product has real buyers.

3
THE BRIGHT SIDE · 3/3
Strong cash, light debt

There is $311.6M in the vault; even if every debt were paid off, $297.5M would remain.

1
THE RISKS · 1/2
Running at a loss

A loss of $13.2M against $234.6M in annual sales.

2
THE RISKS · 2/2
Executives aren’t buying

No clear buy-side message is coming from the executive floor. Council score: 3/10.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, ANAB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: ANAB is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film